JCT  Vol.4 No.3 , May 2013
Combination Therapy of Multiple Micro Trauma Technology on Hepatocellular Carcinoma
ABSTRACT

Objective: To compare efficacy of therapy scheme as Transhepatic Artery Chemoembolization (TACE) + Radiofrequency Ablation (RFA) + Introportal Vein Chemotherapy (PVC) + Percutaneous Ethanol Injection (PEI) therapy (quadruplet group) with TACE + RFA combinational therapy (diad group) in treating hepatocellular carcinoma (HCC). Methods: 25 cases in quadruplet group were treated by TACE for 3 weeks, then by RFA, after 2 months, by PVC + PEI; 23 cases in diad group were treated by TACE for 3 weeks and then by PEI. After completion of each treatment course in both groups, Alphafetoprotein (AFP) was tested 2 months later; abdomen colorful doppler, CT and AFP were retested 6 months later. Results: AFP was significantly decreased in 23 cases of quadruplet group and 20 cases of diad group among those with AFP positive results. 6 months later, examinations of CT, colorful Doppler and AFP in two groups showed: quadruplet group has significantly decreased (X2 = 6.81, P < 0.01) blood supply of cancer tissue and significantly diminished (X2 = 8.29, P < 0.01) tumor size, few cases with AFP elevation (X2 = 5.06, P < 0.05); lower 1 year relapse rate and two years mortality than that in diad group (X2 = 5.30, P < 0.05). Conclusion: TACE + RFA + PVC + PEI combinational therapy is a safe double intervention treatment for HCC scheme with less side effects, which is better than TACE + PEI scheme in killing remnant tumor and reducing relapse.


Cite this paper
X. Li, G. Lu, D. Liu, G. Wang, S. Li and W. Zhuang, "Combination Therapy of Multiple Micro Trauma Technology on Hepatocellular Carcinoma," Journal of Cancer Therapy, Vol. 4 No. 3, 2013, pp. 695-697. doi: 10.4236/jct.2013.43084.
References
[1]   J. Bruix and J. M. Llovet, “Prognostic Prediction and Treatment Strategy in Hepatocellular Carcinoma,” Hepatology, Vol. 35, No. 3, 2002, pp. 519-524. doi:10.1053/jhep.2002.32089

[2]   G. Cabibbo, F. Latteri, M. Antonucci and A. Craxi, “Multimodal Approaches to the Treatment of Hepatocellular Carcinoma,” Nature Clinical Practice: Gastroenterology & Hepatology, Vol. 6, No. 3, 2009, pp. 159-169. doi:10.1038/ncpgasthep1357

[3]   H. X. Xu, X. Y. Xie, M. D. Lu, et al., “Ultrasound-Guided Percutaneous Thermal Ablation for Treatment of Hepatocellular Carcinoma,” Chinese Journal of Hepatobiliary Surgery, Vol. 11, No. 12, 2005, pp. 809-811.

[4]   H. X. Xu, X. Y. Xie, M. D. Lu, et al., “Ultrasound-Guided percutaneous Thermal Ablation of Hepatocellular Carcinoma Using Microwave and Radiofrequency Ablation,” Clinical Radiology, Vol. 59, No. 1, 2004, pp. 52-60. doi:10.1016/j.crad.2003.09.006

[5]   X. L. Du, J. S. Wu, Q. S. Ma, et al., “Transcatheter Hepatic Artery Combolization Helps Radiofrequency Ablation of Hepatic Neoplasms,” Journal of the Fourth Military Medical University, Vol. 21, No. 11, 2000, pp. 1406-1408.

[6]   J.-Y. Wu, W. Yang, M. Cui, et al., “Efficacy and Feasibility of Radiofrequency Ablation for Decompensated Cirrhotic Patients with Hepatocellular Carcinoma,” Chinese Medical Journal, Vol. 123, No. 15, 2010, pp. 1967-1972.

[7]   X. F. Li, G. R. Lu, G. X. Wang, D. X. Lu and S. L. Li, “TACE in Combination with RF in Treatment of Advanced HCC,” Chinese Journal of Hepatobiliary Surgery, Vol. 9, 2003, pp. 23-25.

[8]   X. Y. Yin, M. D. Lu, X. Y. Xie, et al., “Use of Percutaneous Thermal Ablation for Treatment of Reoperable Recurrent Hepatocellular Carcinoma after Liver Resection,” Chinese Journal of Hepatobiliary Surgery, Vol. 12, No. 4, 2006, pp. 243-245.

[9]   D. Chio, H. K. Lim, M. J. Kim, et al., “Recurrent Hepatocellular Carcinoma: Percutanous Radiofrequency Ablation after Hepatectomy,” Radiology, Vol. 230, 2004, pp. 135-141. doi:10.1148/ra diol.2301021182

[10]   M. R. Li, G. D. Ye, H. D. Chen, et al., “Combined Superselective Transcatheter Arterial Chemoembolization and Selective Intraportal Venous Embolization for the Treatment of Inoperable Advanced Primary Liver Cancer,” Chinese Journal of General Surgery, Vol. 19, No. 1, 2004, pp. 12-14.

[11]   H. Taniguchi, T. Daidoh and Y. Shioaki, “Blood Supply and Drug Delivery to Primary and Secondary Human Liver Cancers Studied with in Vivo Bromodeoixyuridine Labeling,” Cancer, Vol. 71, No. 1, 1993, pp. 50-55. doi:10.1002/1097-0142(19930101)71:1<50::AID-CNCR2820710109>3.0.CO;2-T

 
 
Top